BR0017052A - minigenes otimizados e peptìdeos codificados desse modo - Google Patents

minigenes otimizados e peptìdeos codificados desse modo

Info

Publication number
BR0017052A
BR0017052A BRPI0017052-6A BR0017052A BR0017052A BR 0017052 A BR0017052 A BR 0017052A BR 0017052 A BR0017052 A BR 0017052A BR 0017052 A BR0017052 A BR 0017052A
Authority
BR
Brazil
Prior art keywords
optimized
encoded peptides
vaccines
minigenes
relates
Prior art date
Application number
BRPI0017052-6A
Other languages
English (en)
Other versions
BR0017052B1 (pt
Inventor
Alessandro Sette
Robert Chesnut
Brian D Livingston
Denise Marie Baker
Mark J Newman
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of BR0017052A publication Critical patent/BR0017052A/pt
Publication of BR0017052B1 publication Critical patent/BR0017052B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

"MINIGENES OTIMIZADOS E PEPTìDEOS CODIFICADOS DESSE MODO". Esta presente invenção refere-se ao campo de biologia. Em particular, refere-se a vacinas poliepitópicas e a métodos de projeção de tais vacinas para prover imunogenicidade aumentada. Em certas concretizações, as vacinas poliepitópicas são codificadas por um minigene que provê imunogenicidade otimizada do constructo.
BRPI0017052-6B1A 1999-12-28 2000-12-28 Método para a projeção de um constructo poliepitópico e constructo poliepitópico preparado pelo referido método BR0017052B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17339099P 1999-12-28 1999-12-28
PCT/US2000/035568 WO2001047541A1 (en) 1999-12-28 2000-12-28 Optimized minigenes and peptides encoded thereby

Publications (2)

Publication Number Publication Date
BR0017052A true BR0017052A (pt) 2006-03-01
BR0017052B1 BR0017052B1 (pt) 2013-12-24

Family

ID=22631795

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0017052-6B1A BR0017052B1 (pt) 1999-12-28 2000-12-28 Método para a projeção de um constructo poliepitópico e constructo poliepitópico preparado pelo referido método

Country Status (14)

Country Link
EP (1) EP1242108B1 (pt)
JP (2) JP2004512815A (pt)
KR (1) KR100838507B1 (pt)
CN (1) CN1437476A (pt)
AT (1) ATE366582T1 (pt)
AU (1) AU780064B2 (pt)
BR (1) BR0017052B1 (pt)
CA (1) CA2394748A1 (pt)
DE (1) DE60035523T2 (pt)
DK (1) DK1242108T3 (pt)
ES (1) ES2288885T3 (pt)
HK (1) HK1048068B (pt)
MX (1) MXPA02006554A (pt)
WO (1) WO2001047541A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
AU2002950183A0 (en) * 2002-07-12 2002-09-12 The Council Of The Queensland Institute Of Medical Research Expression of hydrophobic proteins
TW200418980A (en) 2002-10-03 2004-10-01 Epimmune Inc Optimized multi-epitope constructs and uses thereof
CA2500715A1 (en) * 2002-10-03 2004-04-15 Epimmune, Inc. Hla binding peptides and their uses
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
EP1687022A4 (en) * 2003-11-12 2008-02-13 Medical Res Council RENTA: HIV IMMUNOGEN, AND USES OF RENTA
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US9511134B2 (en) 2006-05-18 2016-12-06 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
GB0905519D0 (en) * 2009-03-31 2009-05-13 Biofortuna Ltd Assay method and device
DK2714071T3 (da) 2011-05-24 2019-09-16 Biontech Rna Pharmaceuticals Gmbh Individualiserede vacciner mod cancer
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
US9901632B2 (en) 2012-10-19 2018-02-27 The Council Of The Queensland Institute Of Medical Research Human herpesvirus immunotherapy
AU2013351542B2 (en) 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
CN105254719B (zh) * 2015-10-21 2018-07-13 黑龙江八一农垦大学 金黄色葡萄球菌trap蛋白的cd4+t细胞表位鉴定及其重组表位疫苗
JP2020518648A (ja) 2017-05-08 2020-06-25 グリットストーン オンコロジー インコーポレイテッド アルファウイルス新生抗原ベクター
US20200353070A1 (en) * 2018-01-22 2020-11-12 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Selective cd8-positive t cell-inducing vaccine antigen
CA3099644A1 (en) * 2018-05-23 2019-11-28 Gritstone Oncology, Inc. Shared antigens
SG11202113187WA (en) 2019-05-30 2021-12-30 Gritstone Bio Inc Modified adenoviruses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10506004A (ja) * 1994-07-27 1998-06-16 ザ カウンシル オブ ザ クィーンズランド インスティテュート オブ メディカル リサーチ ポリエピトープワクチン
DE69723434T2 (de) * 1996-04-26 2004-05-19 Rijksuniversiteit Te Leiden Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope
ATE311463T1 (de) * 1996-05-24 2005-12-15 Chiron Corp Fusionsprotein mit multiplen epitopen
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
CA2685270C (en) * 1998-05-13 2014-07-29 Pharmexa Inc. Expression vectors for stimulating an immune response and methods of using the same

Also Published As

Publication number Publication date
AU2607501A (en) 2001-07-09
CN1437476A (zh) 2003-08-20
DK1242108T3 (da) 2007-11-12
HK1048068A1 (en) 2003-03-21
EP1242108B1 (en) 2007-07-11
EP1242108A1 (en) 2002-09-25
MXPA02006554A (es) 2003-09-22
KR100838507B1 (ko) 2008-06-17
ATE366582T1 (de) 2007-08-15
CA2394748A1 (en) 2001-07-05
ES2288885T3 (es) 2008-02-01
WO2001047541A1 (en) 2001-07-05
AU780064B2 (en) 2005-02-24
EP1242108A4 (en) 2005-11-02
JP5628716B2 (ja) 2014-11-19
DE60035523D1 (de) 2007-08-23
DE60035523T2 (de) 2008-03-20
JP2011168592A (ja) 2011-09-01
JP2004512815A (ja) 2004-04-30
KR20020084424A (ko) 2002-11-07
HK1048068B (zh) 2008-02-22
BR0017052B1 (pt) 2013-12-24

Similar Documents

Publication Publication Date Title
BR0017052A (pt) minigenes otimizados e peptìdeos codificados desse modo
BR9205783A (pt) Composição biodegradável, processo para produzí-la, e processo de moldá-la.
IL161229A0 (en) Methods and compositions relating to restricted expression lentiviral vectors and their applications.
DE60237701D1 (de) Zusammensetzung zur herstellung von flammwidrigen polurethanweichschaumstoffen
WO2002094002A3 (en) Cultivated agarwood
DE60123389D1 (de) Stabile, wässerige zusammensetzungen zur behandlung von oberflächen , insbesondere geweben
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
MXPA03011505A (es) Composiciones para cabello.
DE50203814D1 (de) Silikonkautschukzusammensetzung zur Herstellung von Kabeln bzw. Profilen
WO2001017543A3 (en) Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
DE60039225D1 (de) Flammhemmende harzzusammensetzung
DE69907408D1 (de) Harzzusammensetzung für kosmetika
DE69924239D1 (de) Halogenfreie flammgeschützte harzzusammensetzung
DE60312211D1 (de) Haarbehandlungsmittel
ITTO20010321A0 (it) Procedimento per la trasmissione di messaggi sms con identita' protetta.
EP1412388A4 (en) HUMANIZED ANTIBODIES DERIVED FROM DD-3B6 / 22, SPECIFIC OF THE FIBRIN D-DIMER FRAGMENT
DE60141616D1 (de) Verfahren zur Herstellung von kleinen, sphärischen Siliconharzpartikeln
BR0207646A (pt) Composição estabilizadora para polìmeros halogenados, uso da mesma e polìmeros que compreendem tais composições
DE69120390D1 (de) Kollagen-bindendes protein sowie dessen herstellung
DE50211951D1 (de) Aufschäumbare Haarbehandlungsmittel
DE69601328D1 (de) Hydroxymethylchinuclidin-Katalysatorzusammensetzungen zur Herstellung von Polyurethanschäumen
ATE212691T1 (de) Verfahren zur herstellung einer langgestreckten barriere
WO1999053091A3 (de) Gdnf-kodierende dna, teile davon und gdnf-varianten
BR9713040A (pt) Xampu condicionador, e, processos de obtenção do mesmo e para limpeza e condicionamento de cabelos.
FR2859228B1 (fr) Pieu qui trouvera notamment son application en tant que piquet de chantier, fiche de paveur, piquet d'implantation ou autres

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/12/2013, OBSERVADAS AS CONDICOES LEGAIS.

B16D Grant of patent or certificate of addition of invention cancelled

Free format text: REFERENTE A RPI 2242 DE 24/12/2013, POR TER SIDO INDEVIDO.

B09Y Publication of grant cancelled [chapter 9.1.2 patent gazette]

Free format text: ANULADA A PUBLICACAO DE DEFERIMENTO POR TER SIDO INDEVIDA.

B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 12A E 13A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2246 DE 21/01/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 12A, 13A, 14A, 15A, 16A, 17A, 18A E 19A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.